Comparison of endogenous 4b-hydroxycholesterol with midazolam as markers for cyp3a4 induction by rifampicin

Drug Metabolism and Disposition

Volumn 41, Issue 8, 2013, Pages 1488-1493

  Björkhem Bergman, Linda ^a   Bäckström, Tobias ^a   Nylén, Hanna ^a   Rönquist Nii, Yuko ^a   Bredberg, Eva ^b   Andersson, Tommy B ^b,c   Bertilsson, Leif ^a   Diczfalusy, Ulf ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c Section of Pharmacogenetics   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

4BETA HYDROXYCHOLESTEROL; 6BETA HYDROXYHYDROCORTISONE; CHOLESTEROL; CHOLESTEROL DERIVATIVE; CYTOCHROME P450 3A4; MIDAZOLAM; RIFAMPICIN; UNCLASSIFIED DRUG; 6 BETA-HYDROXYCORTISOL; BIOLOGICAL MARKER; CHOLEST 5 ENE 3,4 DIOL; CHOLEST-5-ENE-3,4-DIOL; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; DRUG DERIVATIVE; HYDROCORTISONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG INTERACTION; ENZYME ANALYSIS; ENZYME INDUCTION; FEMALE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TANDEM MASS SPECTROMETRY; TREATMENT DURATION; URINALYSIS; URINE LEVEL; BIOSYNTHESIS; BLOOD; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; METABOLIC CLEARANCE RATE; METABOLISM; URINE;

ADULT; BIOLOGICAL MARKERS; CHOLESTEROL; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; ENZYME INDUCTION; FEMALE; HUMANS; HYDROCORTISONE; HYDROXYCHOLESTEROLS; MALE; METABOLIC CLEARANCE RATE; MIDAZOLAM; RIFAMPIN;

EID: 84880687241     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.052316     Document Type: Article

References (27)

1. Backman JT, Olkkola KT, Ojala M, Laaksovirta H, and Neuvonen PJ (1996) Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia 37:253-257.
2. Bodin K, Bretillon L, Aden Y, Bertilsson L, Broomé U, Einarsson C, and Diczfalusy U (2001) Antiepileptic drugs increase plasma levels of 4b-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. J Biol Chem 276:38685-38689.
3. Diczfalusy U, Kanebratt KP, Bredberg E, Andersson TB, Böttiger Y, and Bertilsson L (2009) 4bhydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin. Br J Clin Pharmacol 67:38-43.
4. Diczfalusy U, Miura J, Roh HK, Mirghani RA, Sayi J, Larsson H, Bodin KG, Allqvist A, Jande M, and Kim JW, et al. (2008) 4b-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet Genomics 18:201-208.
5. Diczfalusy U, Nylén H, Elander P, and Bertilsson L (2011) 4b-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. Br J Clin Pharmacol 71:183-189.
6. Dostalek M, Macwan JS, Chitnis SD, Ionita IA, and Akhlaghi F (2010) Development and validation of a rapid and sensitive assay for simultaneous quantification of midazolam, 19-hydroxymidazolam, and 4-hydroxymidazolam by liquid chromatography coupled to tandem mass-spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 878:1629-1633.
7. Fromm MF, Schwilden H, Bachmakov I, König J, Bremer F, and Schüttler J (2007) Impact of the CYP3A5 genotype on midazolam pharmacokinetics and pharmacodynamics during intensive care sedation. Eur J Clin Pharmacol 63:1129-1133.
8. Fuhr U, Jetter A, and Kirchheiner J (2007) Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach. Clin Pharmacol Ther 81:270-283.
9. Galteau MM and Shamsa F (2003) Urinary 6b-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur J Clin Pharmacol 59:713-733.
10. Gerber JG, Rosenkranz SL, Fichtenbaum CJ, Vega JM, Yang A, Alston BL, Brobst SW, Segal Y, and Aberg JA; AIDS Clinical Trials Group A5108 Team (2005) Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defic Syndr 39:307-312.
11. Habtewold A, Amogne W, Makonnen E, Yimer G, Nylén H, Riedel KD, Aderaye G, Bertilsson L, Burhenne J, and Diczfalusy U, et al. (2012) Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients. Pharmacogenomics J DOI:10.1038/tpj.2012.46.
12. Hassan R, Ameen SS, Al Maruf A, Nandini A, Tabin H, Ahmed MU, Islam MS, Bin Sayeed MS, and Hasnat A (2013) Genotype-phenotype variability in human CYP3A locus in Nepalese people residing in Bangladesh. Int J Clin Pharmacol Ther 51:207-214.
13. Josephson F, Bertilsson L, Böttiger Y, Flamholc L, Gisslén M, Ormaasen V, Sönnerborg A, and Diczfalusy U (2008) CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4b-hydroxycholesterol levels. Eur J Clin Pharmacol 64: 775-781.
14. Kaartama R, Jarho P, Savolainen J, Kokki H, and Lehtonen M (2011) Determination of midazolam and 1-hydroxymidazolam from plasma by gas chromatography coupled to methane negative chemical ionization mass spectrometry after sublingual administration of midazolam. J Chromatogr B Analyt Technol Biomed Life Sci 879:1668-1676.
15. Kanebratt KP, Diczfalusy U, Bäckström T, Sparve E, Bredberg E, Böttiger Y, Andersson TB, and Bertilsson L (2008) Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4b-hydroxycholesterol. Clin Pharmacol Ther 84:589-594.
16. Kharasch ED, Walker A, Isoherranen N, Hoffer C, Sheffels P, Thummel K, Whittington D, and Ensign D (2007) Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin Pharmacol Ther 82:410-426.
17. Li D, Abudula A, Abulahake M, Zhu AP, Lou YQ, and Zhang GL (2010) Influence of CYP3A5 and MDR1 genetic polymorphisms on urinary 6 b-hydroxycortisol/cortisol ratio after grapefruit juice intake in healthy Chinese. J Clin Pharmacol 50:775-784.
18. Lütjohann D, Marinova M, Schneider B, Oldenburg J, von Bergmann K, Bieber T, Björkhem I, and Diczfalusy U (2009) 4b-hydroxycholesterol as a marker of CYP3A4 inhibition in vivo -effects of itraconazole in man. Int J Clin Pharmacol Ther 47:709-715.
19. Mårde Arrhén Y, Nylén H, Lövgren-Sandblom A, Kanebratt KP, Wide K, and Diczfalusy U (2013) A comparison of 4b-hydroxycholesterol/cholesterol and 6b-hydroxycortisol/cortisol as markers of CYP3A4 induction. Br J Clin Pharmacol 75:1536-1540.
20. Miao J, Jin Y, Marunde RL, Gorski CJ, Kim S, Quinney S, Radovich M, Li L, and Hall SD (2009) Association of genotypes of the CYP3A cluster with midazolam disposition in vivo. Pharmacogenomics J 9:319-326.
21. Mirghani RA, Ericsson O, Tybring G, Gustafsson LL, and Bertilsson L (2003) Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man. Eur J Clin Pharmacol 59:23-28.
22. Mirghani RA, Sayi J, Aklillu E, Allqvist A, Jande M, Wennerholm A, Eriksen J, Herben VM, Jones BC, and Gustafsson LL, et al. (2006) CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population. Pharmacogenet Genomics 16:637-645.
23. Pal D and Mitra AK (2006) MDR-and CYP3A4-mediated drug-drug interactions. J Neuroimmune Pharmacol 1:323-339.
24. Rogers JF, Nafziger AN, Kashuba AD, Streetman DS, Rocci ML, Jr., Choo EF, Wilkinson GR, and Bertino JS, Jr. (2002) Single plasma concentrations of 19-hydroxymidazolam or the ratio of 19-hydroxymidazolam:midazolam do not predict midazolam clearance in healthy subjects. J Clin Pharmacol 42:1079-1082.
25. Tomalik-Scharte D, Doroshyenko O, Kirchheiner J, Jetter A, Lazar A, Klaassen T, Frank D, Wyen C, Fätkenheuer G, and Fuhr U (2008) No role for the CYP3A53 polymorphism in intestinal and hepatic metabolism of midazolam. Eur J Clin Pharmacol 64:1033-1035.
26. Wide K, Larsson H, Bertilsson L, and Diczfalusy U (2008) Time course of the increase in 4bhydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy. Br J Clin Pharmacol 65:708-715.
27. Zhang W, Han F, Guo P, Zhao H, Lin ZJ, Huang MQ, Bertelsen K, and Weng N (2010) Simultaneous determination of tolbutamide, omeprazole, midazolam and dextromethorphan in human plasma by LC-MS/MS-A high throughput approach to evaluate drug-drug interactions. J Chromatogr B Analyt Technol Biomed Life Sci 878:1169-1177.